CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties

Combination regimens are a standard of care for many cancers. However, components of such regimens are typically first developed individually and subsequently combined using strategies to minimize toxicity. Little or no consideration is given to strategies that potentially maximize efficacy. In cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer, Lawrence D, Tardi, Paul, Louie, Arthur C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537039/
https://www.ncbi.nlm.nih.gov/pubmed/31213803
http://dx.doi.org/10.2147/IJN.S139450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537039/
https://www.ncbi.nlm.nih.gov/pubmed/31213803
http://dx.doi.org/10.2147/IJN.S139450

Ejemplares similares